Jean Michel Dela Vedova-Costa

Jean Michel Dela Vedova-Costa

Auto-generated profile, based on publicly available information

Jean Michel Dela Vedova-Costa

Laboratório de Biologia Molecular, Programa de Pós Graduação em Engenharia de Bioprocessos e Biotecnologia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Brazilian Archives of Biology and Technology
Verified
Journal Article
Open access
JVJean Michel Dela Vedova-Costa
Jean Michel Dela Vedova-Costa
EREliezer Lucas Pires Ramos
Eliezer Lucas Pires Ramos
RBRaphael Aparecido Boschero
Raphael Aparecido Boschero
GFGabriela Nascimento Ferreira
Gabriela Nascimento Ferreira
VSVANETE THOMAZ SOCCOL
VANETE THOMAZ SOCCOL
CSCarlos Ricardo Soccol
Carlos Ricardo Soccol

24 February 2025 in ACS Omega
Verified
Journal Article
Open access
VPVioletta Dias Pacce
Violetta Dias Pacce
AGAmanda Munari Guimarães
Amanda Munari Guimarães
FKFrederico Schmitt Kremer
Frederico Schmitt Kremer
GFGabriela Nascimento Ferreira
Gabriela Nascimento Ferreira
JVJean Michel Dela Vedova-Costa
Jean Michel Dela Vedova-Costa
VSVANETE THOMAZ SOCCOL
VANETE THOMAZ SOCCOL
Bovine tuberculosis (bTB) is a respiratory disease caused by Mycobacterium bovis, posing a significant threat to animal health and the livestock industry. Current control strategies for bTB rely on diagnostic tests and slaughter policies. However, the limitations of existing diagnostic methods, which depend on PPD antigens, necessitate the exploration of alternative antigens to enhance the accuracy and reliability of bTB diagnosis. This study aimed to identify, produce, and evaluate novel antigens for use in the intradermal skin test for bTB diagnosis. A pangenome analysis of four Mycobacterium species identified 12 unique genes specific to M. bovis SP38. Further integrated bioinformatic analysis revealed 224 genomic islands associated with virulence and pathogenesis. Among these, a highly antigenic protein, termed HP28, was selected for in vivo testing. The recombinant HP28 protein (rHP28) was expressed in E. coli and assessed for its ability to induce intradermal skin reactions in guinea pigs. The rHP28 protein elicited a skin reaction of 6.6 mm at 72 h post-injection, whereas negative controls showed no reaction. This study presents a pipeline for the selection of antigens using integrated bioinformatic analysis to identify diagnostic targets that can effectively distinguish between sensitized and non-sensitized animals, offering a promising approach for improving bTB diagnostics.